Sodium channel gating modulator eases motor deficits in zebrafish model of spinal muscular atrophy
- Neuronal hyperexcitability driven by voltage-gated sodium channels is proposed as a contributor to spinal muscular atrophy, which could be targeted alongside SMN-restoring therapies.
- In a zebrafish smn1 knockout model, the venom peptide ProTx-III, the approved drug riluzole and the N-type calcium channel blocker ziconotide were compared for effects on movement and lifespan.
- Sodium channel modulation improved locomotion and survival, with ProTx-III outperforming riluzole, while ziconotide gave limited benefit. Electrophysiology showed ProTx-III shifted gating broadly, whereas riluzole mainly stabilised the inactivated state.
💡 Points Based on the abstract
Zebrafish larvae can't tell you whether this works in SMA patients, and a venom peptide that hits NaV subtypes broadly is a tool, not a drug. Ask which subtype drives the motor neuron hyperexcitability, and whether human SMA neurons show it too. Without that, riluzole-class stabilisers, with real clinical exposure data, remain the pragmatic comparator.